This is the first study to demonstrate that patients with sarcoma experienced ifosfamide-induced encephalopathy more often than those with lymphoma. For all patients, predisposing factors for ifosfamide-induced encephalopathy included previous cisplatin exposure, concomitant opioids and CYP2B6 inhibitors. Laboratory values that increased ifosfamide-induced encephalopathy risk included low serum albumin, increased serum creatinine, and increased hemoglobin.
Background Oncology pharmacists are capable of providing medication therapy management (MTM) because of their level of training, practice experiences, and responsibilities. Very little data exist about their current practice, including changing roles in the multidisciplinary team, overall impact, and effects in the education of patients and healthcare professionals. Methods A 70-item survey about oncology pharmacists' activities in oral chemotherapy programs, MTM, and collaborative practice agreements (CPAs) was deployed using a web survey tool (Qualtrics, Provo, UT, USA), targeting pharmacist members of American College of Clinical Pharmacy (ACCP) Hematology/Oncology Practice and Research Network (PRN). The objective of this study was to determine oncology pharmacists' activities in areas of oral chemotherapy programs, MTM, and CPAs. A cross-sectional survey was distributed to the ACCP Hematology/Oncology PRN membership. Investigational Review Board approval was obtained. Results Of the 795 members who were sent the survey, 81 members (10%) responded; 33 respondents (47%) are involved with an oral chemotherapy program; with 42% measuring outcomes of programs. Only six pharmacists (19%) have published or presented their data. A total of 28 (35%) respondents provide MTM services, with almost half (43%) of these MTM services being dictated by CPAs. A small fraction of these pharmacists (21.4%) reported conducting quality assurance evaluations of their MTM services and three pharmacists (10.7%) reported publishing their results. Those pharmacists practicing under CPAs ( n = 28) were surveyed as to activities included in their CPA. The most common activities included adjusting medication, ordering, interpreting, and monitoring lab tests, developing therapeutic plans and educating patients. Reimbursement for providing these services was uncommon: MTM (4%), oral chemotherapy program (6%), and CPA services (11%). Reported obstacles to reimbursement included lack of understanding, administrative assistance, or time with setting up reimbursement models within the institution. Conclusion Many oncology pharmacists are participating in oral chemotherapy programs, MTM, and/or CPAs and perceived barriers were identified. Increased efforts should be directed toward prospectively reporting and assessing the impact these services have on patient care.
Docetaxel-associated palmar-plantar erythrodysesthesia is rarely reported in literature, particularly when used in the treatment of sarcomas. Here, we report a case of docetaxel-related palmar-plantar erythrodysesthesia in a 28-year-old male with recurrent Ewing sarcoma. Although palmar-plantar erythrodysesthesia has been seen in the literature for 30 years, there has still been little progress in understanding and appropriately addressing this adverse effect. This case report and literature review illustrates an infrequently documented adverse skin reaction and discusses the etiology, presentation, and available treatment options for palmar-plantar erythrodysesthesia.
Competency standards in pharmacy education and training have been formulated by different organizations to focus on various stages in the development of students, residents, and clinical pharmacists. This commentary advocates a deliberate alignment of educational outcomes, goals, and competencies across the developmental continuum of students, residents, and pharmacy practitioners. Consistent use of terminology and appropriate sequencing of expectations will help develop pharmacists who can meet the demands of the profession in the changing health care landscape.Progressive development is needed for the pharmacist's abilities, from student to resident to new practitioner to experienced professional. Consistency will ensure that educational and training programs optimally prepare individuals for board certification and professional roles. Specific recommendations include developing a common taxonomy that aligns within the pharmacy profession and across health care professions. K E Y W O R D Sclinical pharmacist, pharmacist competency, pharmacy education
High-quality experiential education builds on didactic education to enable graduates to meet the full spectrum of entry-level pharmacy-related roles and responsibilities, including lifelong learning and professional development. The 2019 Educational Affairs Committee A, an ACCP standing committee, was charged to review and update the 2008 ACCP white paper and position statement on quality experiential education. The main objective of this white paper is to provide colleges and schools of pharmacy (C/SOPs) and affiliated partners in experiential education with practices expected to assist in achieving excellence in experiential education and fulfilling the goal of developing fully competent practice-and team-ready pharmacy graduates. K E Y W O R D Sclinical pharmacist, experiential education, preceptors
The goal of this research was to design a solution to detect non-reported incidents of injection. METHODS: We developed methods to process electronic medical records and automatically extract clinical notes describing incidents of injection by using the SVM based technique. First, we manually labeled a training set of clinical notes into two categories based on whether they included an incident report of injection or not, and then the machine learning models were created. This machine learning method arranges data in a vector space, using single words as the axes. For the training process, a few variations were tested: normalized versus non-normalized data. The extracted notes are treated as incident candidates which are shown to the safety management department for further analysis. RESULTS: Using the developed method based on the SVM, we implemented an incident candidate reporting system. To evaluate the system, we asked a staff of the safety management department to judge whether extracted incident candidates were incidents or not. The system used inpatients' clinical notes written from January 8, 2018 to January 14, 2018 in Kyoto University Hospital. As a result, in the case of non-normalized data, 41 out of 364 incident candidates were judged clinical notes describing incidents. Furthermore, 21 of them were nonreported incidents. In the case of normalized data, 23 out of 91 incident candidates were judged clinical notes describing incidents. Moreover, 13 of them were nonreported incidents. CONCLUSIONS: In this research, we aimed to establish a method to extract incident candidates from clinical notes in order to detect nonreported incidents of injection. In addition, we created a reporting system that presents incident candidates extracted by using the developed method. The system successfully detected non-reported incidents to the safety management department, thus our goal was achieved.
117 (46%) with bisphosphonates and 19 (7%) with Ra-223. Further to this; 79% of these Ra-223 patients were also administered abiraterone or enzalutamide versus 21% who used it alone. Of patients on Ra-223, 11% had only bone metastases while 89% had bone plus one or more additional metastases. The majority of patients on Ra-223 had Gleason scores below 8 (84% ≤ 7). The average (median) PSA level was 114 (110) and 111 (40) at diagnosis and treatment, respectively. The average (median) time from diagnosis to development of CRPC was 375 days (305). ConClusions: Bone-targeted therapy is still dominated by denosumab and bisphosphonates. However, Ra-223 is the first BTA to actually improve survival. The real-world data used in this analysis shows that Ra-223 is not only used in patients whose cancer has spread to the bones but also in those whose cancer has spread to other organs. Though commonly administered with abiraterone or enzalutamide, Ra-223 is also given alone. The majority of patients treated with Ra-223 show a Gleason score of 7 and the average (median) PSA values are lower at treatment than at diagnosis. The analysis of Ra-223 patients has also identified the average time from diagnosis to development of CRPC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.